Media
Documents:
Photos:
Audio/Podcasts:
Biography
Born in Gdansk, Poland, Dr. Gospodarowicz is a medical graduate of the University of Toronto. She earned specialty certifications in internal medicine, radiation oncology and medical oncology, and in 1978, joined the staff at Princess Margaret Hospital. In 2001, Dr. Gospodarowicz was named chief of the Radiation Medicine Program, and in 2005, she was appointed medical director of Princess Margaret Hospital, as well as regional vice-president of Cancer Care Ontario.
A member of the University of Toronto medical faculty since 1981, Dr. Gospodarowicz recently completed two terms as professor and chair of the Department of Radiation Oncology. She has an active clinical practice in which she treats patients with lymphomas and genitourinary cancers. She is the author of more than 250 peer-reviewed articles and book chapters, with her research interests including clinical trials evaluating radiation therapy in cancer treatment, image-guided precision radiotherapy, and survivorship.
Her numerous roles at the provincial, national and international levels have included president of the Canadian Association of Radiation Oncology and chair of the Canadian Committee on Cancer Staging. She is an honorary fellow of the U.K. Royal College of Radiologists, a fellow of the American Society of Therapeutic Radiology and Oncology, and honorary member of the European Society of Therapeutic Radiology and Oncology.
Industry Expertise (6)
Health Care - Services
Health Care - Providers
Health Care - Facilities
Research
Advanced Medical Equipment
Public Policy
Areas of Expertise (8)
Clinical Research
Health Policy
Radiation Therapy
Strategic Planning
Epidemology
Radiation Oncology
Programs At Princess Margaret Cancer Centre
International Cancer Programming
Education (3)
Royal College of Physicians and Surgeons of Canada: Fellow, Radiation Oncology
Royal College of Physicians and Surgeons (U.K): Fellow, (Hon)
University of Toronto: MD, Medicine
Affiliations (5)
- University of Toronto, Department of Radiation Oncology : Professor
- Cancer Care Ontario, Toronto South Region : Regional Vice President
- TNM Project, UICC : Chair
- Union for International Cancer Control : President
- Clinical Studies Resource Centre : Member
Media Appearances (2)
UICC President Balances Innovation and Pragmatism to Reduce the Global Burden of Cancer
The ASCO Post online
2013-06-10
Interviewed by Ronald Piana on her approaches to furthering cancer research and care.
Princess Margaret Hospital’s Mary Gospodarowicz fighting cancer worldwide
The Toronto Star online
2012-11-16
Dr. Mary Gospodarowicz is Princess Margaret Hospital’s medical director and the first Canadian head of the Union for International Cancer Control. But she insists: “It’s not about me.”
Event Appearances (1)
Janeway Lecture
American Radium Society 95th Annual Meeting Scottsdale, AZ.
2014-04-27
Articles (2)
Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience
International Journal Radiation Oncology, Biology, Physics
1984-04-01
A total of 1,394 patients with non-Hodgkin's lymphoma were treated at the Princess Margaret Hospital between January 1, 1967 and December 31, 1978. Overall actuarial survival of 525 patients with nodular lymphomas was 40% at 12 years; survival of patients with localized (Stage 1 > III) nodular lymphomas treated with radical radiation therapy was 58%. Significant prognostic factors defined by multivariate analysis included patient's age, stage, histology, tumor bulk, and presence of B symptoms. By combining prognostic factors we have identified distinct prognostic groups within the overall population. Patients with Stage I > II disease, small or medium bulk, less than 70 years of age achieved 92% 12 year actuarial survival and a 73% relapse-free rate in 12 years of follow-up. These patients represent groups highly curable with irradiation.
Patient management scenario: A framework for clinical decision and prognosis
Seminars in Surgical Oncology
2003-01-01
The depiction of prognosis is one of the main activities and a mainstay in medical practice. In cancer, as in other diseases, the prognosis differs for a variety of situations and evolves with time and with medical interventions. Although most commonly described at diagnosis, prognosis may be defined at any time during the course of the disease and for any endpoint including response to therapy, failure of treatment, survival, or preservation of function, and so forth. To facilitate the accurate portrayal of the future, the prognosis should be defined within a specific setting, referred to as a ‘management scenario’. In the concept of a management scenario, the prognosis is defined using systematically considered prognostic factors, interventions and the outcome of interest. A deliberate and careful determination of prognosis is essential to clinical decision making and patient care. We illustrate the use of the concept of management scenario in several clinical examples.
Social